Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that develops and sells treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. The company operates in Australia, Europe, the United States, Switzerland, and internationally. Its primary drug candidate is SCENESSE, a systemic photoprotective drug designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP). Clinuvel's product pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue, and PRÉNUMBRA, which is a liquid injectable formulation of afamelanotide. The company is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone aimed at neurological, endocrinological, and degenerative disorders. Furthermore, Clinuvel is working on pharmaceutical formulations using melanocortin technology to treat various disorders. Beyond pharmaceuticals, the company offers photocosmetic products. These products are intended for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and who require assistance with DNA repair and melanogenesis of the skin. Clinuvel Pharmaceuticals Ltd was incorporated in 1999 and has its headquarters in Melbourne, Australia.